New scan could catch lung disease before symptoms start

NCT ID NCT05417776

Recruiting now Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special PET scan that uses a radioactive tracer to find collagen buildup in the lungs, a sign of early scarring. Researchers will scan 30 people, including relatives of patients with pulmonary fibrosis and those with early lung abnormalities. The goal is to see if this scan can detect interstitial lung disease sooner than current methods.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]CBP8 (a radioactive tracer) and Dotarem (an MRI contrast agent)
What this could lead to: If successful, this imaging method could help detect lung scarring earlier, allowing for timely treatment and better outcomes.
What could go wrong: This is a small, early-phase study focused on imaging, not treatment. The tracer may not reliably distinguish early disease from normal tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERSTITIAL LUNG DISEASE

Contacts and locations

Locations

Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.